Roberto Luzzati

8.0k total citations · 1 hit paper
158 papers, 3.9k citations indexed

About

Roberto Luzzati is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Roberto Luzzati has authored 158 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Infectious Diseases, 61 papers in Epidemiology and 32 papers in Surgery. Recurrent topics in Roberto Luzzati's work include Antifungal resistance and susceptibility (19 papers), Antibiotic Resistance in Bacteria (17 papers) and Infective Endocarditis Diagnosis and Management (16 papers). Roberto Luzzati is often cited by papers focused on Antifungal resistance and susceptibility (19 papers), Antibiotic Resistance in Bacteria (17 papers) and Infective Endocarditis Diagnosis and Management (16 papers). Roberto Luzzati collaborates with scholars based in Italy, United States and France. Roberto Luzzati's co-authors include Stefano Di Bella, Ercole Concia, Daniele Roberto Giacobbe, Matteo Bassetti, Roberta Maria Antonello, Jacopo Monticelli, Bruna Marini, Bojana Lucic, Mauro Giacca and Hashim Ali and has published in prestigious journals such as Nature, Neurology and Clinical Microbiology Reviews.

In The Last Decade

Roberto Luzzati

147 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options

2024 39 citations Stefano Di Bella, Gianfranco Sanson et al. profile →

Peers

Countries citing papers authored by Roberto Luzzati

Since Specialization

Citations

This map shows the geographic impact of Roberto Luzzati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Luzzati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Luzzati more than expected).

Fields of papers citing papers by Roberto Luzzati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Luzzati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Luzzati. The network helps show where Roberto Luzzati may publish in the future.

Co-authorship network of co-authors of Roberto Luzzati

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Luzzati. A scholar is included among the top collaborators of Roberto Luzzati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Luzzati. Roberto Luzzati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin 2025 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), Roberto Luzzati, Jacopo Monticelli, (unknown), (unknown), Stefano Di Bella	0
2	Prediction of 30‐day mortality after surgery for infective endocarditis using risk scores: Insights from a European multicenter comparative validation study 2024 ·American Heart Journal ·Giuseppe Gatti, Antonio Fiore, (unknown), (unknown), (unknown), (unknown), Giulia Barbati, Pascal Lim, R. Lepeule, Ilaria Franzese, (unknown), Sandro Sponga, Enrico Fabris, Roberto Luzzati, Gianfranco Sinagra, Giuseppe Biondi‐Zoccai, Giacomo Frati, Andréa Perrotti, Igor Vendramin, Enzo Mazzaro	1
3	A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY) 2024 ·Anaerobe ·Nicholas Geremia, Gianfranco Sanson, Luigi Principe, Roberta Maria Antonello, Verena Zerbato, Roberto Luzzati, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
4	Performance of 16S rRNA Gene Next-Generation Sequencing and the Culture Method in the Detection of Bacteria in Clinical Specimens 2024 ·Diagnostics ·(unknown), Giuseppina Campisciano, Verena Zerbato, Stefano Di Bella, (unknown), Marina Busetti, Dan Alexandru Țoc, Roberto Luzzati, Manola Comar	7
5	BioFire® Joint Infection Panel for Samples Other than Synovial Fluid 2024 ·Antibiotics ·N. Benvenuto, Stefano Di Bella, Luigi Principe, (unknown), (unknown), (unknown), Manuela Di Santolo, Marina Busetti, Roberto Luzzati, Verena Zerbato	1
6	Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life 2023 ·Pharmaceuticals ·Luca Cegolon, (unknown), (unknown), Francesca Larese Filon, Roberto Luzzati	25
7	Infezioni in Medicina 2023 ·Infezioni in Medicina ·(unknown), Verena Zerbato, Stefano Di Bella, Roberto Luzzati, Fábio Cavalli	2
8	Enterococcal meningitis associated with Strongyloides infection: a case report and literature review 2023 ·Infezioni in Medicina ·(unknown), Stefano Di Bella, Roberto Luzzati, (unknown), Maurizio Pinamonti, (unknown), (unknown)	0
9	Candida lipolytica Bloodstream Infection in an Adult Patient with COVID-19 and Alcohol Use Disorder: A Unique Case and a Systematic Review of the Literature 2023 ·Antibiotics ·(unknown), Verena Zerbato, (unknown), (unknown), Francesca Zorat, (unknown), Manuela Di Santolo, (unknown), Stefano Di Bella, Luigi Principe, Roberto Luzzati	2
10	Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment 2023 ·Journal of Chemotherapy ·(unknown), Jacopo Monticelli, Stefano Di Bella, (unknown), Roberto Luzzati	2
11	A urokinase-associated outbreak of Ralstonia mannitolilytica bloodstream infections in haemodialysis patients in north-eastern Italy, January to April 2023 2023 ·Eurosurveillance ·(unknown), (unknown), (unknown), Marina Busetti, Emmanouil Alexandros Fotakis, Christina Merakou, R. Koncan, (unknown), Camilla Negri, (unknown), (unknown), Alberto Antonelli, Marco Coppi, Gian María Rossolini, Claudia Giuliani, (unknown), (unknown), Danilo Licastro, Roberto Luzzati, (unknown), (unknown)	3
12	Uncommon lymphocutaneous cellulitis after insect bite: a case report of primary cutaneous nocardiosis and literature review 2022 ·Infezioni in Medicina ·(unknown), (unknown), Stefano Di Bella, Nicola di Meo, Roberto Luzzati	3
13	Aspirin and Infection: A Narrative Review 2022 ·Biomedicines ·Stefano Di Bella, Roberto Luzzati, Luigi Principe, Verena Zerbato, (unknown), Mauro Giuffrè, Lory Saveria Crocè, Marco Merlo, Maria Perotto, (unknown), (unknown), (unknown), (unknown), Cristina Lagatolla, Bruna Marini, Rudy Ippodrino, Gianfranco Sanson	13
14	Extra-Intestinal Effects of C. difficile Toxin A and B: An In Vivo Study Using the Zebrafish Embryo Model 2020 ·Cells ·Federica Tonon, Stefano Di Bella, Gabriele Grassi, Roberto Luzzati, Paolo Ascenzi, Alessandra di Masi, Cristina Zennaro	6
15	Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies 2020 ·Antibiotics ·Roberta Maria Antonello, Luigi Principe, Alberto Enrico Maraolo, (unknown), (unknown), Massimiliano Fabbiani, Francesca Montagnani, (unknown), Roberto Luzzati, Stefano Di Bella	52
16	Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice 2020 ·Antibiotics ·Stefano Di Bella, Bojana Beovič, Massimiliano Fabbiani, (unknown), Roberto Luzzati	5
17	Cellulosimicrobium cellulans aortic prosthetic valve endocarditis 2019 ·Access Microbiology ·Jacopo Monticelli, (unknown), Claudio Farina, Anna Knezevich, Franca Dore, Roberto Luzzati	3
18	Aseptic central nervous system infections in adults: what predictor for unknown etiological diagnosis? 2018 ·Neurological Sciences ·Jacopo Monticelli, Nicholas Geremia, Pierlanfranco D’Agaro, (unknown), Roberto Luzzati	9
19	Molecular diagnosis of opportunistic pericardial infection in a patient treated with adalimumab: the role of next-generation sequencing 2016 ·BMJ Case Reports ·Stefano Poli, Manola Comar, Roberto Luzzati, Gianfranco Sinagra	0
20	Bilateral internal thoracic artery grafting in octogenarians: where are the benefits? 2015 ·Heart and Vessels ·Giuseppe Gatti, (unknown), Bernardo Benussi, Lorella Dreas, Gabriella Forti, Marco Gabrielli, (unknown), Roberto Luzzati, Gianfranco Sinagra, Aniello Pappalardo	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact